DDInter44 DDInter1376
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Alfuzosin {u} (Compound) resembles {v} (Compound) Terazosin
Alfuzosin {u} (Compound) resembles {v} (Compound) Prazosin
Alfuzosin {u} (Compound) binds {v} (Gene) ADRA1A
Alfuzosin {u} (Compound) upregulates {v} (Gene) PAK1
Alfuzosin {u} (Compound) downregulates {v} (Gene) RBM34
Alfuzosin {u} (Compound) causes {v} (Side Effect) Coronary artery disease
Alfuzosin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Alfuzosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabilone
Alfuzosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Morphine
Alfuzosin {u} may lead to a major life threatening interaction when taken with {v} Cobicistat
Alfuzosin (Compound) resembles Terazosin (Compound)
Alfuzosin (Compound) resembles Prazosin (Compound)
Alfuzosin (Compound) binds ADRA1A (Gene)
Alfuzosin (Compound) upregulates PAK1 (Gene)
Alfuzosin (Compound) downregulates RBM34 (Gene)
Alfuzosin (Compound) causes Coronary artery disease (Side Effect)
Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Nabilone
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Alfuzosin may lead to a major life threatening interaction when taken with Cobicistat